Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

DIABETES

Treating T2DM and obesity with bariatric surgery and GLP1 agents

Bariatric surgery often produces remission of hyperglycaemia in patients with coexistent obesity and type 2 diabetes mellitus, but the hyperglycaemia is prone to return years later. A prospective study demonstrates that therapy with a glucagon-like peptide 1 receptor agonist can reinstate normal glycaemic control in many of these patients.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Rubino, F. et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care. 39, 861–877 (2016).

    CAS  Article  Google Scholar 

  2. 2.

    Schauer, P. R. et al. Bariatric surgery versus intensive medical therapy for diabetes — 5-year outcomes. N. Engl. J. Med. 376, 641–651 (2017).

    Article  Google Scholar 

  3. 3.

    Adams, T. D. et al. Weight and metabolic outcomes 12 years after gastric bypass. N. Engl. J. Med. 377, 1143–1155 (2017).

    Article  Google Scholar 

  4. 4.

    Steinert, R. E. et al. Ghrelin, CCK, GLP-1, and PYY(3–36): secretory controls and physiological roles in eating and glycemia in health, obesity, and after RYGB. Physiol. Rev. 97, 411–463 (2017).

    Article  Google Scholar 

  5. 5.

    Nannipieri, M. et al. Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones. J. Clin. Endocrinol. Metab. 98, 4391–4399 (2013).

    CAS  Article  Google Scholar 

  6. 6.

    Hutch, C. R. & Sandoval, D. The role of GLP-1 in the metabolic success of bariatric surgery. Endocrinology 158, 4139–4151 (2017).

    Article  Google Scholar 

  7. 7.

    Lim, S., Kim, K. M. & Nauck, M. A. Glucagon-like peptide-1 receptor agonists and cardiovascular events: class effects versus individual patterns. Trends Endocrinol. Metab. 29, 238–248 (2018).

    CAS  Article  Google Scholar 

  8. 8.

    Bailey, C. J. & Marx, N. Cardiovascular protection in type 2 diabetes: insights from recent outcome trials. Diabetes Obes. Metab. 21, 3–14 (2019).

    Article  Google Scholar 

  9. 9.

    Gorgojo-Martínez, J. J., Feo-Ortega, G. & Serrano-Moreno, C. Effectiveness and tolerability of liraglutide in patients with type 2 diabetes mellitus and obesity after bariatric surgery. Surg. Obes. Relat. Dis. 12, 1856–1863 (2016).

    Article  Google Scholar 

  10. 10.

    Miras, A. D. et al. Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. https://doi.org/10.1016/S2213-8587(19)30157-3 (2019).

    Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Clifford J. Bailey.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bailey, C.J. Treating T2DM and obesity with bariatric surgery and GLP1 agents. Nat Rev Endocrinol 15, 504–506 (2019). https://doi.org/10.1038/s41574-019-0240-4

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing